开云app官网登录入口网页版-官方正版

#PAH#

27篇内容 | 1513人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1460211, encodeId=c3eb14602113f, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=Chest：通过 PAH 中的活动记录评估日常生活中的身体活动：来自司来帕格 (TRACE) 随机对照研究的见解, objectType=article, longId=739329, objectId=e177e3932903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e177e3932903, replyNumber=0, likeNumber=77, createdTime=2022-09-16, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e177e3932903, moduleTitle=Chest：通过 PAH 中的活动记录评估日常生活中的身体活动：来自司来帕格 (TRACE) 随机对照研究的见解, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e177e3932903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460210, encodeId=e761146021026, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=【每日播报】-SLE-PAH的临床分型, objectType=article, longId=737693, objectId=205fe3769397, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=205fe3769397, replyNumber=0, likeNumber=64, createdTime=2022-09-04, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=205fe3769397, moduleTitle=【每日播报】-SLE-PAH的临床分型, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=205fe3769397)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460209, encodeId=45d4146020972, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=【每日播报】-PAH作为肺血管病变的病理表现, objectType=article, longId=737691, objectId=c8ade37691ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8ade37691ea, replyNumber=0, likeNumber=61, createdTime=2022-09-04, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8ade37691ea, moduleTitle=【每日播报】-PAH作为肺血管病变的病理表现, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c8ade37691ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460208, encodeId=c3fb14602084b, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=【每日播报】-PAH的严重性评估, objectType=article, longId=737690, objectId=6fe1e3769053, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fe1e3769053, replyNumber=0, likeNumber=57, createdTime=2022-09-04, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fe1e3769053, moduleTitle=【每日播报】-PAH的严重性评估, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6fe1e3769053)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460207, encodeId=b8fe146020e7b, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=European radiology：肺动脉高压(PAH)、肺静脉闭塞性疾病及肺毛细血管血管瘤并(PVOD/PCH)的双能量CT肺灌注特征, objectType=article, longId=732057, objectId=d467e3205704, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d467e3205704, replyNumber=0, likeNumber=78, createdTime=2022-07-12, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d467e3205704, moduleTitle=European radiology：肺动脉高压(PAH)、肺静脉闭塞性疾病及肺毛细血管血管瘤并(PVOD/PCH)的双能量CT肺灌注特征, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d467e3205704)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460206, encodeId=04d91460206c0, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=JAMA：肺动脉高压（PAH）的常见临床表现, objectType=article, longId=727943, objectId=a266e2794385, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a266e2794385, replyNumber=0, likeNumber=110, createdTime=2022-05-28, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a266e2794385, moduleTitle=JAMA：肺动脉高压（PAH）的常见临床表现, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a266e2794385)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460205, encodeId=3225146020557, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=肺动脉高压（PAH）的亚组都有哪些？, objectType=article, longId=727898, objectId=3b4de2789833, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b4de2789833, replyNumber=0, likeNumber=0, createdTime=2022-05-27, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b4de2789833, moduleTitle=肺动脉高压（PAH）的亚组都有哪些？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3b4de2789833)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460204, encodeId=99ff146020466, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=JAMA：肺动脉高压（PAH）最新定义、病理生理学和患病率, objectType=article, longId=727712, objectId=2b22e277129d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b22e277129d, replyNumber=0, likeNumber=83, createdTime=2022-05-25, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b22e277129d, moduleTitle=JAMA：肺动脉高压（PAH）最新定义、病理生理学和患病率, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2b22e277129d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460203, encodeId=e94d146020330, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=PAH与PH-HFpEF如何区别, objectType=article, longId=727283, objectId=1736e27283ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1736e27283ba, replyNumber=0, likeNumber=100, createdTime=2022-05-20, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1736e27283ba, moduleTitle=PAH与PH-HFpEF如何区别, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1736e27283ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460202, encodeId=64b414602028b, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=AJRCCM：B细胞去除治疗系统性硬化症相关性肺动脉高压(SSC-PAH)的安全性和有效性, objectType=article, longId=218717, objectId=b364218e1739, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b364218e1739, replyNumber=0, likeNumber=64, createdTime=2021-10-18, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b364218e1739, moduleTitle=AJRCCM：B细胞去除治疗系统性硬化症相关性肺动脉高压(SSC-PAH)的安全性和有效性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b364218e1739)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460201, encodeId=02451460201d4, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=ERJ：将 IL-6 作为 PAH 药物靶点的孟德尔随机化和实验医学方法, objectType=article, longId=218064, objectId=38be21806437, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38be21806437, replyNumber=0, likeNumber=105, createdTime=2021-10-04, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38be21806437, moduleTitle=ERJ：将 IL-6 作为 PAH 药物靶点的孟德尔随机化和实验医学方法, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=38be21806437)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460200, encodeId=8c711460200b2, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=Lancet Respirat Med：长期应用ASK1抑制剂Selonsertib是否可降低PAH患者的肺血管阻力？, objectType=article, longId=216127, objectId=ab2e21612efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab2e21612efa, replyNumber=0, likeNumber=84, createdTime=2021-08-23, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab2e21612efa, moduleTitle=Lancet Respirat Med：长期应用ASK1抑制剂Selonsertib是否可降低PAH患者的肺血管阻力？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ab2e21612efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460199, encodeId=a7971460199ef, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=【盘点】肺动脉高压（PAH）近期重要研究进展汇总, objectType=article, longId=193258, objectId=a59f19325849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a59f19325849, replyNumber=0, likeNumber=101, createdTime=2020-05-02, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a59f19325849, moduleTitle=【盘点】肺动脉高压（PAH）近期重要研究进展汇总, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a59f19325849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460198, encodeId=e336146019895, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=Congenit Heart Dis：法舒地尔可以改善CHD-PAH患者的血流动力学，特别是60-mg剂量, objectType=article, longId=192115, objectId=ffc4192115cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffc4192115cf, replyNumber=0, likeNumber=53, createdTime=2020-04-14, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffc4192115cf, moduleTitle=Congenit Heart Dis：法舒地尔可以改善CHD-PAH患者的血流动力学，特别是60-mg剂量, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ffc4192115cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460197, encodeId=f550146019e03, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=Pulm Circ：血清生存素代表了反映CHD-PAH患者可操作性的候选生物标志物, objectType=article, longId=191713, objectId=8524191e13a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8524191e13a6, replyNumber=0, likeNumber=58, createdTime=2020-04-09, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8524191e13a6, moduleTitle=Pulm Circ：血清生存素代表了反映CHD-PAH患者可操作性的候选生物标志物, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8524191e13a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460196, encodeId=9e551460196a5, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=Ann Rheum Dis：初始联合使用安立生坦和他达拉非治疗结缔组织病相关性肺动脉高压（CTD-PAH）, objectType=article, longId=190265, objectId=f699190265d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f699190265d6, replyNumber=0, likeNumber=57, createdTime=2020-03-20, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f699190265d6, moduleTitle=Ann Rheum Dis：初始联合使用安立生坦和他达拉非治疗结缔组织病相关性肺动脉高压（CTD-PAH）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f699190265d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460195, encodeId=6be5146019591, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=LIQ861（曲前列环素）吸入粉治疗肺动脉高压（PAH）, objectType=article, longId=186913, objectId=bec8186913fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec8186913fc, replyNumber=0, likeNumber=71, createdTime=2020-01-30, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec8186913fc, moduleTitle=LIQ861（曲前列环素）吸入粉治疗肺动脉高压（PAH）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=bec8186913fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460194, encodeId=675b146019429, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=肺动脉高压（PAH）治疗的Sotatercept达到II期研究的主要终点, objectType=article, longId=186904, objectId=685a1869048d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=685a1869048d, replyNumber=0, likeNumber=66, createdTime=2020-01-30, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=685a1869048d, moduleTitle=肺动脉高压（PAH）治疗的Sotatercept达到II期研究的主要终点, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=685a1869048d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460193, encodeId=c5bc14601933c, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=Int J Cardiol：右心室收缩期与舒张期持续时间比值为PAH成人的预后因素, objectType=article, longId=165678, objectId=14741656e853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14741656e853, replyNumber=0, likeNumber=64, createdTime=2019-05-10, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14741656e853, moduleTitle=Int J Cardiol：右心室收缩期与舒张期持续时间比值为PAH成人的预后因素, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=14741656e853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460192, encodeId=058d146019235, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, objectTitle=Eur Heart J-Card Img：静息时右心室功能与PAH患者运动表现相关！, objectType=article, longId=129662, objectId=f3d4129662c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3d4129662c4, replyNumber=0, likeNumber=108, createdTime=2018-02-13, rootId=0, userName=hb2010ye, userId=87966261195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3d4129662c4, moduleTitle=Eur Heart J-Card Img：静息时右心室功能与PAH患者运动表现相关！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f3d4129662c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

PAH

2020-05-29

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

Chest：通过 PAH 中的活动记录评估日常生活中的身体活动：来自司来帕格 (TRACE) 随机对照研究的见解

2022-09-16

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

【每日播报】-SLE-PAH的临床分型

2022-09-04

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

【每日播报】-PAH作为肺血管病变的病理表现

2022-09-04

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

【每日播报】-PAH的严重性评估

2022-09-04

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

European radiology：肺动脉高压(PAH)、肺静脉闭塞性疾病及肺毛细血管血管瘤并(PVOD/PCH)的双能量CT肺灌注特征

2022-07-12

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

JAMA：肺动脉高压（PAH）的常见临床表现

2022-05-28

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

肺动脉高压（PAH）的亚组都有哪些？

2022-05-27

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

JAMA：肺动脉高压（PAH）最新定义、病理生理学和患病率

2022-05-25

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

PAH与PH-HFpEF如何区别

2022-05-20

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

AJRCCM：B细胞去除治疗系统性硬化症相关性肺动脉高压(SSC-PAH)的安全性和有效性

2021-10-18

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

ERJ：将 IL-6 作为 PAH 药物靶点的孟德尔随机化和实验医学方法

2021-10-04

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

Lancet Respirat Med：长期应用ASK1抑制剂Selonsertib是否可降低PAH患者的肺血管阻力？

2021-08-23

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

【盘点】肺动脉高压（PAH）近期重要研究进展汇总

2020-05-02

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

Congenit Heart Dis：法舒地尔可以改善CHD-PAH患者的血流动力学，特别是60-mg剂量

2020-04-14

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

Pulm Circ：血清生存素代表了反映CHD-PAH患者可操作性的候选生物标志物

2020-04-09

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

Ann Rheum Dis：初始联合使用安立生坦和他达拉非治疗结缔组织病相关性肺动脉高压（CTD-PAH）

2020-03-20

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

LIQ861（曲前列环素）吸入粉治疗肺动脉高压（PAH）

2020-01-30

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

肺动脉高压（PAH）治疗的Sotatercept达到II期研究的主要终点

2020-01-30

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

Int J Cardiol：右心室收缩期与舒张期持续时间比值为PAH成人的预后因素

2019-05-10

hb2010ye (审核中...)

前往app查看评论内容

#PAH#

Eur Heart J-Card Img：静息时右心室功能与PAH患者运动表现相关！

2018-02-13

科室
- - 订阅+
  - 更多科室
工具
服务